***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: To evaluate the clinical effectiveness of chlorpromazine in comparison with placebo over a brief period of hospitalization , the authors conducted a double-blind study of the drug in 44 acutely ill schizophrenic patients . These patients had been newly admitted to a brief treatment unit where the average length of stay was 7 to 10 days . The results of this study indicate that chlorpromazine had no more calming or antipsychotic effect than placebo during the first 5 days of treatment . The authors suggest that 5 days is too short a time for a clinical trial to gauge patient response to chlorpromazine Summary Trifluperidol , a new butyrophenone compound , was evaluated in chronic schizophrenic women under conditions of a controlled clinical trial . Within this framework significant drug effects associated with the st and ard drug , chlorpromazine , attested to the sensitivity of the experiment , while trifluperidol , the experimental drug , was shown to be an antipsychotic agent at least equally as effective as the st and ard . The placebo group tended to deteriorate on all measures . This trend did not differ significantly from a similar trend in a group of subjects receiving neither placebo nor active treatment . The most likely explanation for this deterioration is thought to be an inadequate preliminary dry-out period , although other influences affecting all subjects adversely can not be ruled out . The demonstration of significant drug : placebo differences was dependent in part upon the presence of the negative change in the placebo group . Failure to include a control group in the present study would have precluded the demonstration of statistically significant drug effects In a series of 6 separate controlled clinical trials of  antipsychotic agents in chronic schizophrenic patients , it was shown repeatedly that chlorpromazine ( CPZ ) exhibited hypercholesterolemic activity . In the analysis of covariance , the adjusted final mean difference in serum cholesterol concentrations between the placebo and  CPZ  groups ranged from 14 to 28 mg . per 100 ml . This activity was dose related in that it occurred with a fixed daily dose of 600 mg . administered for 24 weeks , but not with a fixed daily dose of 150 mg . or 300 mg . over the same period of time . The serum concentration of triglycerides remained unaffected under similar experimental conditions . This action of CPZ appeared unrelated to thyroid function and liver function as presently measured in the clinical laboratory . A consistent relationship to body weight changes could not be demonstrated even though increased body weight was noted to be a consistent result of CPZ therapy . In view of its extensive use as long‐term therapy , the possible role of CPZ as an atherogenic agent deserves consideration A double-blind placebo-controlled trial of chlorpromazine , using a cross-over design , is reported . There were 28 patients , showing chronic defect states , mostly schizophrenic . They lived in an isolated community , and were selected because they had had no specific therapy for at least five years , and had had no previous treatment with psychotropic drugs of any kind . Pre caution s were taken to keep their environment constant , and medication was not started until the end of a six-month observation period , in which all the procedures of a therapeutic trial , including administration of placebo , were carried out . Only one patient out of 28 showed a definite therapeutic response . Analysis of ratings for the main psychopathological symptoms did not disclose any significant changes in the group as a whole . It is argued that the value of chlorpromazine in chronic schizophrenia has been accepted without sufficient evidence of the effect of the drug in different clinical states and the specific indications for its use . Further study of the clinical features of cases which do or do not respond to phenothiazines is required 
    Output:
    
There were , however , many adverse effects .
Chlorpromazine is sedating ( n = 1242 , 18 RCTs , RR 2.3 CI 1.7 to 3.1 , NNH 6 CI 5 to 8) , increases a person 's chances of experiencing acute movement disorders , Parkinsonism and causes low blood pressure with dizziness and dry mouth .
Conclusion It is underst and able why the World Health Organization ( WHO ) have endorsed and included chlorpromazine in their list of essential drugs for use in schizophrenia .